SOLUBLE LOX-1 (SLOX-1) AS A PROMISING BIOMARKER IN ISCHEMIC HEART DISEASE AND ACUTE CORONARY SYNDROME
Received: 2026-06-18 18:26:54
Published: 2025-12-21
Abstract
In recent years, growing attention has focused on the soluble lectin-like oxidized LDL receptor (sLOX-1) as a promising biomarker in coronary artery disease (CAD) and acute coronary syndrome (ACS). This review summarizes eleven studies from 2020–2025, including eight major clinical trials. It discusses LOX-1 activation, the role of sLOX-1 in vascular inflammation and plaque instability, and its diagnostic and prognostic significance. Elevated sLOX-1 levels are closely linked to myocardial infarction risk, post-ACS mortality, and coronary damage. The review also outlines key sensitivity, specificity, and prognostic data, emphasizing the clinical relevance of sLOX-1
Keywords
List of references
About the Authors
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
